Latest News

  • Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder Read More
  • Alkermes Demonstrates Commitment to Local Community for 11th Consecutive Year With Largest Volunteer Event in Company History Read More
  • Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma Read More

Investors

Working at Alkermes